Metabolism, Excretion, and Pharmacokinetics of [C-14]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans (original) (raw)

Abstract

The goal of this study was to evaluate the pharmacokinetics, mass balance, metabolism, routes and extent of elimination, and safety of a single oral dose of 14 C-labeled brivanib alaninate and the safety and tolerability of brivanib after multiple doses in patients with advanced or metastatic solid tumors. This was a two-part, single-center, open-label, single oral-dose (part A) followed by multiple-dose (part B) study in patients with advanced or metastatic solid tumors. In part A, patients received a single dose of [ 14 C]brivanib alaninate and in part B patients received 800 mg of nonradiolabeled brivanib alaninate every day. Four patients (two white, two black: two with non-small-cell lung cancer, one with ovarian cancer, and one with renal cell carcinoma) were treated in both parts. The median time to reach the maximal plasma concentration of brivanib was 1 h, geometric mean maximal plasma con-centration was 6146 ng/ml, mean terminal half-life was 13.8 h, and geometric mean apparent oral clearance was 14.7 l/h. After a single oral dose of [ 14 C]brivanib alaninate, 12.2 and 81.5% of administered radioactivity was recovered in urine and feces, respectively. Brivanib alaninate was completely converted to the active moiety, brivanib, and the predominant route of elimination was fecal. Renal excretion of unchanged brivanib was minimal. Brivanib was well tolerated; fatigue was the most frequent adverse event occurring in all patients and the most frequent treatment-related adverse event in three (75%). The best clinical response in one patient was stable disease; the other three had progressive disease. Brivanib alaninate was rapidly absorbed and extensively metabolized after a single 800-mg oral dose; the majority of drugrelated radioactivity was excreted in feces. (2009) Mass balance, pharmacokinetics and metabolism of 14 C of brivanib in subjects with advanced or metastatic solid tumors. to reach maximum observed plasma concentration; AUC 0-inf , area under the concentration-time curve from time 0 extrapolated to infinity; AUC 0-T , AUC from time 0 to the last quantifiable concentration; t 1/2 , terminal elimination half-life; CLR, renal clearance; CL/F, apparent total body clearance.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (23)

  1. Arora A and Scholar EM (2005) Role of tyrosine kinase inhibitors in cancer therapy. J Phar- macol Exp Ther 315:971-979.
  2. Beumer JH, Beijnen JH, and Schellens JH (2006) Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet 45:33-58.
  3. Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, et al. (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H- indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49:2143-2146.
  4. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R Sr, Mortillo S, Wautlet BS, Krishnan B, et al. (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9:369 -378.
  5. Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, et al. (2008) Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5- yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 51:1976 -1980.
  6. Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249 - 257.
  7. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, et al. (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134.
  8. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, et al. (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35.
  9. Hartmann JT, Haap M, Kopp HG, and Lipp HP (2009) Tyrosine kinase inhibitors-a review on pharmacology, metabolism and side effects. Curr Drug Metab 10:470 -481.
  10. Hurwitz H, LoRusso P, Shapiro I, Wolanski A, Chemidlin J, Masson E, Syed S, Kollia G, Fischer B, and Conlon K (2008) Phase 1 study of food effects on pharmacokinetics of brivanib alaninate in patients with advanced or metastatic solid tumors, in Proceedings of the 20th EORTC-NCI-AACR Symposium on "Molecular Targets and Cancer Therapeutics"; 2008 October 21-24; Geneva, Switzerland. Abstr 429, European CanCer Organisation, Brussels, Belgium.
  11. Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, et al. (2008) Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 14:6146 -6153.
  12. Je Y, Schutz FA, and Choueiri TK (2009) Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 10:967-974.
  13. Kane RC, Farrell AT, Saber H, Tang S, Williams G, Jee JM, Liang C, Booth B, Chidambaram N, Morse D, et al. (2006) Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12:7271-7278.
  14. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, et al. (2008a) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698 -711.
  15. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al. (2008b) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378 -390.
  16. Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, and Fargnoli J (2009) Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate. Cancer Chemother Pharmacol 65:55-66.
  17. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G, Desai A, Hwang J, Villalona-Calero MA, Dees EC, et al. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27:1800 -1805.
  18. Morabito A, De Maio E, Di Maio M, Normanno N, and Perrone F (2006) Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11:753-764.
  19. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, et al. (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124.
  20. Nyberg P, Xie L, and Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65:3967-3979.
  21. Raoul J-L, Finn R, Kang YK, Park JW, Harris R, Coric V, Donica M, and Walters I (2009) An open-label phase II study of first-and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC) (abstract). J Clin Oncol 27(15s):abstr 4577.
  22. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, and Johnson DH (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550.
  23. van Erp NP, Gelderblom H, and Guchelaar HJ (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 35:692-706.